openPR Logo
Press release

Biopharma PEG Expands Multi-Arm PEG Product Line

08-28-2024 08:39 AM CET | Chemicals & Materials

Press release from: Biopharma PEG Scientific Inc

Biopharma PEG, a leader in PEG derivatives, is excited to announce the expansion of its high-purity Multi-Arm PEG linker product line, catering to the evolving needs of the medical and bioorganic fields. These advanced PEG linkers are available in various functional groups and molecular weights ranging from 1k to 40k, offering unmatched versatility and performance for research and development in cutting-edge medical applications.
"Biopharma PEG is committed to delivering high-purity multi-arm PEG linkers with diverse functional groups and molecular weights from 1k to 40k," said Sonia Lee, Biopharma PEG. "Our multi-arm PEG derivatives are widely recognized as smart cross-linkers, and they have been extensively studied for their ability to form hydrogels. These hydrogels are pivotal in medical devices, regenerative medicine, drug delivery systems, 3D cell culture, and wound healing."
Diverse Product Offering: Biopharma PEG's multi-arm PEG products are available with various branching structures and functional groups to meet the specific needs of researchers and developers in the medical and bioorganic fields. Key product categories include:
 2-Arm PEG (Y-shape PEG, branched PEG): Ideal for applications requiring a branched structure, such as Y-shape-PEG-NHS.
 4-Arm PEG: Available in options like 4-ArmPEG-SG, 4-ArmPEG-SS, and 4-ArmPEG-NH2, these linkers provide enhanced cross-linking capabilities.
 8-Arm PEG: Examples include 8-ArmPEG-SG, 8-ArmPEG-SS, and 8-ArmPEG-Mal, offering maximum branching for complex hydrogel formation.
These products are offered in molecular weights of MW 2k, MW 5k, MW 10k, MW 20k, and MW 40k, allowing for precise control over the physical and chemical properties of the final hydrogel structures. The total molecular weight of each multi-arm PEG product is calculated as the sum of the molecular weights of the PEG chains on each arm.
Key Applications in Medicine: Multi-arm PEG linkers from Biopharma PEG are vital in several advanced medical applications:
 Controlled Drug Release: The cross-linked hydrogels formed by multi-arm PEGs provide a stable matrix for the sustained and controlled release of drugs, ensuring targeted delivery and enhanced therapeutic efficacy.
 3D Cell Culture: Multi-arm PEG hydrogels create a supportive, biocompatible environment that mimics natural tissue, making them ideal for 3D cell culture and tissue engineering.
 Wound Sealing and Healing: Multi-arm PEG hydrogels are increasingly used in wound care, offering effective sealing properties that promote faster healing and reduce the risk of infection.
Custom Solutions for Specialized Needs: In addition to the standard product offerings, Biopharma PEG provides custom synthesis of multi-arm PEGs with specific molecular weights and functional groups not listed in the online catalog. This allows researchers and developers to tailor PEG linkers to their unique project requirements. Inquiries for custom synthesis can be directed to sales@biochempeg.com, where our team is ready to assist with pricing and availability.
Contact Information: For more details on Biopharma PEG's high-purity multi-arm PEG linkers or to explore custom synthesis options, please visit www.biochempeg.com or reach out to our team at sales@biochempeg.com.

Biopharma PEG Scientific Inc.
108 Water Street, Suite 4D, Watertown, MA 02472, USA
TEL: 1-857-928-2050 / 1-857-366-6766
Fax: 617-206-9595
Email: sales@biochempeg.com

Biopharma PEG is a premier supplier of PEG derivatives, committed to advancing the pharmaceutical, biotechnology, and medical device industries with innovative products that enhance the performance of therapeutic agents. Discover more at www.biochempeg.com.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biopharma PEG Expands Multi-Arm PEG Product Line here

News-ID: 3636890 • Views:

More Releases from Biopharma PEG Scientific Inc

Biopharma PEG Offers In-Stock Monodispersed PEGs at Competitive Prices
Biopharma PEG Offers In-Stock Monodispersed PEGs at Competitive Prices
Biopharma PEG Scientific Inc. announced the availability of a broad range of in-stock monodispersed PEG derivatives at highly competitive prices, supporting researchers working in antibody-drug conjugates (ADCs), nanoparticle and LNP delivery systems, diagnostics, and biomaterials. Biopharma PEG specializes in PEG derivatives, including monodispersed, polydispersed, and multi-arm PEGs, offered in both GMP and non-GMP grades. By keeping key monodispersed PEGs on the shelf and ready to ship, the company aims to help
Biopharma PEG Highlights the Critical Role of PEG-Lipid Nanoparticles in RNA The …
Watertown, MA, September 26, 2025 - In the past decade, lipid nanoparticles (LNPs) have emerged as the premier delivery vehicle for RNA-based medicines, powering the success of both siRNA drugs and mRNA vaccines. A key component of these systems is PEG-lipids, specialized polyethylene glycol (PEG) derivatives that stabilize nanoparticles, extend circulation time, and enhance safety. Why PEG-Lipids Are Essential RNA molecules are inherently unstable in the bloodstream, where they are rapidly degraded
BIOPHARMA PEG Receives FDA DMF Listings for Two Key PEG Derivatives
BIOPHARMA PEG, a leading developer and supplier of high-purity polyethylene glycol (PEG) derivatives, today announced that two of its proprietary products-mPEG-pALD 20K and HZ-PEG-HZ (1K)-have successfully passed FDA review and are now listed in the U.S. Drug Master File (DMF) database. mPEG-pALD (20K) - DMF No. 040600 HZ-PEG-HZ (1K) - DMF No. 041864 These new listings mark a significant step in BIOPHARMA PEG's ongoing efforts to provide regulatory-ready, high-quality PEG solutions to the
Monodispersed PEG Linkers Enhance Antibody-Drug Conjugates (ADCs)
Antibody-drug conjugates (ADCs) combine potent small-molecule drugs with monoclonal antibodies for targeted cancer therapy. A major challenge is loading enough drug onto each antibody without compromising solubility or circulation time. Introducing polyethylene glycol (PEG) linkers between the antibody and drug payload can address this. PEG is hydrophilic, biologically inert, and FDA‐recognized as safe. As a flexible spacer, PEG "shields" the hydrophobic drug, greatly improving ADC solubility and stability. In fact,

All 5 Releases


More Releases for Key

Mobile Office Market Size, Share and Forecast By Key Players-Key Player I, Key P …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Mobile Office market is anticipated to grow at a compound annual growth rate (CAGR) of 15.39% between 2024 and 2031. The market is expected to grow to USD 8.1 Billion by 2024. The valuation is expected to reach USD 22.04 Billion by 2031. With more people seeking flexible work arrangements, the market for mobile offices is expanding significantly. Businesses are embracing mobile
Olivine Sand Market Size, Share and Forecast By Key Players-Key Player I, Key Pl …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Olivine Sand market is anticipated to grow at a compound annual growth rate (CAGR) of 16.07% between 2024 and 2031. The market is expected to grow to USD 39 Billion by 2024. The valuation is expected to reach USD 110.69 Billion by 2031. The olivine sand market is poised for significant growth due to its increasing use in
Excimer Lamps Market Size, Share and Forecast By Key Players-Key Player I, Key P …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Excimer Lamps market is anticipated to grow at a compound annual growth rate (CAGR) of 8.46% between 2024 and 2031. The market is expected to grow to USD 11.09 Billion by 2024. The valuation is expected to reach USD 19.58 Billion by 2031. The need for excimer lamps is rising significantly across a number of industries, including semiconductor manufacturing, healthcare, and environmental
4-Tert-Butyl Benzaldehyde Market Size, Trends 2031 By Key Players- Key Player I, …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲: According to Verified Market Reports analysis, the global 4-Tert-Butyl Benzaldehyde Market size was valued at USD 100 Million in 2023 and is expected to reach USD 140.5Million by the end of 2031 with a CAGR of 5.7% during the forecast period 2024-2031. The 4-Tert-Butyl Benzaldehyde Market presents significant opportunities for growth driven by various factors. One key opportunity lies in the expanding applications of 4-tert-butyl benzaldehyde as a
Tri N pentylamine Market Size, Potential Scope 2031 By Key Players- Key Player I …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲: According to Verified Market Reports analysis, the global Tri N pentylamine Market size is reached a valuation of USD xx.x Billion in 2023, with projections to achieve USD xx.x Billion by 2031, demonstrating a 𝐂𝐀𝐆𝐑 𝐗𝐗.𝐗% 𝐟𝐫𝐨𝐦 𝟐𝟎𝟐𝟒 𝐭𝐨 𝟐𝟎𝟑𝟏. The Tri N pentylamine Market presents notable opportunities for growth driven by various factors. One significant opportunity lies in the increasing demand for tri N pentylamine as a
Isobutyl Benzene (IBB) Market Size, Insights 2031 by Key Vendors- Key Player I, …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲: According to Verified Market Reports analysis, the global Isobutyl Benzene (IBB) Market size was valued at USD 18.2 Million in 2023 and is expected to reach USD 25.4 Million by the end of 2031 with a CAGR of 5.15% During the Forecast Period 2024-2031. The Isobutyl Benzene (IBB) market presents promising opportunities driven by its versatile applications across various industries, including chemicals, pharmaceuticals, and plastics. Isobutyl benzene is